Table 2
Open in new tab

Clinical predictors of TO and TS in group 1 subjects at univariate linear regression analysis

TOP-valueTSP-value
Age1.05 (1.034–1.071)<0.0010.83 (0.80–86)<0.001
Male gender0.82 (0.44–1.51)0.526.47 (1.54–27)0.011
Mean heart rate0.99 (0.96–1.03)0.770.94 (0.88–1.01)0.068
CVRFs
 Hypertension2.78 (1.52–5.05)0.0010.01 (0.01–0.04)<0.001
 Dyslipidemia2.14 (1.15–3.99)0.0170.12 (0.03–0.50)0.004
 Smoke0.57 (0.25–1.27)0.1695.39 (0.79–36)0.084
 Obesity1.03 (0.66–1.59)0.8820.52 (0.19–1.45)0.213
Therapy
 β-Blockers1.34 (0.69–2.58)0.3810.19 (0.04–0.92)0.040
 Ca2+-antagonists1.86 (0.82–4.22)0.1350.05 (0.01–0.30)0.002
 ACE-inhibitors1.87 (0.91–3.88)0.0880.04 (0.01–0.22)<0.001
 Statins1.73 (0.76–3.91)0.1900.04 (0.01–0.24)0.001
 Diuretics2.10 (0.99–4.47)0.0520.06 (0.01–0.37)0.002
LVEF0.96 (0.89–1.03)0.2381.13 (0.94–1.35)0.194
TOP-valueTSP-value
Age1.05 (1.034–1.071)<0.0010.83 (0.80–86)<0.001
Male gender0.82 (0.44–1.51)0.526.47 (1.54–27)0.011
Mean heart rate0.99 (0.96–1.03)0.770.94 (0.88–1.01)0.068
CVRFs
 Hypertension2.78 (1.52–5.05)0.0010.01 (0.01–0.04)<0.001
 Dyslipidemia2.14 (1.15–3.99)0.0170.12 (0.03–0.50)0.004
 Smoke0.57 (0.25–1.27)0.1695.39 (0.79–36)0.084
 Obesity1.03 (0.66–1.59)0.8820.52 (0.19–1.45)0.213
Therapy
 β-Blockers1.34 (0.69–2.58)0.3810.19 (0.04–0.92)0.040
 Ca2+-antagonists1.86 (0.82–4.22)0.1350.05 (0.01–0.30)0.002
 ACE-inhibitors1.87 (0.91–3.88)0.0880.04 (0.01–0.22)<0.001
 Statins1.73 (0.76–3.91)0.1900.04 (0.01–0.24)0.001
 Diuretics2.10 (0.99–4.47)0.0520.06 (0.01–0.37)0.002
LVEF0.96 (0.89–1.03)0.2381.13 (0.94–1.35)0.194

CVRFs, cardiovascular risk factors; ACE, angiotensin converting enzyme; LVEF, left ventricular ejection fraction.

Table 2
Open in new tab

Clinical predictors of TO and TS in group 1 subjects at univariate linear regression analysis

TOP-valueTSP-value
Age1.05 (1.034–1.071)<0.0010.83 (0.80–86)<0.001
Male gender0.82 (0.44–1.51)0.526.47 (1.54–27)0.011
Mean heart rate0.99 (0.96–1.03)0.770.94 (0.88–1.01)0.068
CVRFs
 Hypertension2.78 (1.52–5.05)0.0010.01 (0.01–0.04)<0.001
 Dyslipidemia2.14 (1.15–3.99)0.0170.12 (0.03–0.50)0.004
 Smoke0.57 (0.25–1.27)0.1695.39 (0.79–36)0.084
 Obesity1.03 (0.66–1.59)0.8820.52 (0.19–1.45)0.213
Therapy
 β-Blockers1.34 (0.69–2.58)0.3810.19 (0.04–0.92)0.040
 Ca2+-antagonists1.86 (0.82–4.22)0.1350.05 (0.01–0.30)0.002
 ACE-inhibitors1.87 (0.91–3.88)0.0880.04 (0.01–0.22)<0.001
 Statins1.73 (0.76–3.91)0.1900.04 (0.01–0.24)0.001
 Diuretics2.10 (0.99–4.47)0.0520.06 (0.01–0.37)0.002
LVEF0.96 (0.89–1.03)0.2381.13 (0.94–1.35)0.194
TOP-valueTSP-value
Age1.05 (1.034–1.071)<0.0010.83 (0.80–86)<0.001
Male gender0.82 (0.44–1.51)0.526.47 (1.54–27)0.011
Mean heart rate0.99 (0.96–1.03)0.770.94 (0.88–1.01)0.068
CVRFs
 Hypertension2.78 (1.52–5.05)0.0010.01 (0.01–0.04)<0.001
 Dyslipidemia2.14 (1.15–3.99)0.0170.12 (0.03–0.50)0.004
 Smoke0.57 (0.25–1.27)0.1695.39 (0.79–36)0.084
 Obesity1.03 (0.66–1.59)0.8820.52 (0.19–1.45)0.213
Therapy
 β-Blockers1.34 (0.69–2.58)0.3810.19 (0.04–0.92)0.040
 Ca2+-antagonists1.86 (0.82–4.22)0.1350.05 (0.01–0.30)0.002
 ACE-inhibitors1.87 (0.91–3.88)0.0880.04 (0.01–0.22)<0.001
 Statins1.73 (0.76–3.91)0.1900.04 (0.01–0.24)0.001
 Diuretics2.10 (0.99–4.47)0.0520.06 (0.01–0.37)0.002
LVEF0.96 (0.89–1.03)0.2381.13 (0.94–1.35)0.194

CVRFs, cardiovascular risk factors; ACE, angiotensin converting enzyme; LVEF, left ventricular ejection fraction.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close